Q-omics provides the consensus-scored ACTBP14 profile across patient tissues and cancer cell-line models. ACTBP14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ACTBP14 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, ACTBP14 RNA expression shows 6,662 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, THCA, and STAD as cancer lineages where ACTBP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTBP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTBP14 survival associations across molecular data types. ACTBP14 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTBP14 RNA expression–survival associations across cancer types. High ACTBP14 expression shows unfavorable associations in LIHC, BLCA and CHOL, but favorable associations in MESO, SKCM and KIRP. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ACTBP14 RNA expression.
This table summarizes ACTBP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ACTBP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTBP14 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BRCA, COAD and LUAD. The THCA box plot shows higher ACTBP14 RNA expression in normal versus tumor tissue (log2 FC = −0.049, t-test p < 0.001).
This table shows molecular features associated with ACTBP14 in patient tissues and cancer cell lines. In patient samples, ACTBP14 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
